Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era

Cancer

Volumn 79, Issue 7, 1997, Pages 1370-1380

  Zagars, Gunar K ^a   Pollack, Alan ^a   Von Eschenbach, Andrew C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Gleason score; prognostic factors; prostate carcinoma; prostate specific antigen; radiation therapy; T classification

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RELAPSE; TUMOR VOLUME;

AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030903419     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970401)79:7<1370::AID-CNCR15>3.0.CO;2-X     Document Type: Article

References (26)

1. Zagars GK. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:47-53.
2. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11:2158-66.
3. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efrid JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-5.
4. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh DC. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-25.
5. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821-5.
6. Catalona WJ, Smith DS. 5-year recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1821-5.
7. Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: long-term results. J Urol 1994;1781-5.
8. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer: analysis of 874 patients treated with radiation therapy. Cancer 1993;72:1709-25.
9. Swanson GP, Cupps RE, Utz DC, Ilstrup DM, Zincke H, Myers RP. Definitive therapy for prostate carcinoma: Mayo Clinic results at 15 years after treatment. Br J Radiol 1994;67:877-89.
10. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:293-306.
11. Zagars GK, Pollack A, von Eschenbach AC. Prostate cancer and radiation therapy: the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995;33:23-35.
12. Zagars GK, Geara FB, Pollack A, von Eschenbach AC. The T classification of clinically localized prostate cancer: an appraisal based on disease outcome following radiation therapy. Cancer 1994;73:1904-12.
13. Zagars GK, Ayala AG, von Eschenbach AC, Pollack A. The prognostic significance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 1995;31:237-45.
14. Zagars GK, Sands ME, Pollack A, von Eschenbach AC. Early androgen ablation for Stage D1 (N1 to N3, MO) prostate cancer: prognostic variables and outcome. J Urol 1994;151:1330-3.
15. Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 1995;45:476-83.
16. Roy AV, Bower ME, Hayden JE. Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem 1971;17:1093-1102.
17. Pollack A, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL, Rosen IL Conventional versus conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996;34:555-64.
18. Zagars GK, von Eschenbach AC. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiotherapy. Cancer 1993;72:538-48.
19. Harris EK, Albert A. Survivorship analysis for clinical studies. New York: Dekker, 1991:5-125.
20. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984:110-20.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons, 1989:22-134.
22. U.S. Department of Health, Education, and Welfare. Vital Statistics of the United States, 1988. Hyattsville, Maryland: Public Health Service National Center for Health Statistics.
23. Pollack A, Lankford S, Zagars GK, Babaian RJ. PSA density as a prognostic factor in prostate cancer patients treated with radiotherapy. Cancer 1996;77:1515-23.
24. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:456-9.
25. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152:1826-30.
26. Pollack A, Zagars GK, Kopplin S. Radiotherapy and androgen ablation for clinically localized high risk prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:13-20.